Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
      • 1-Minute Consult
      • Commentary
      • Current Drug Therapy
      • Editorial
      • Guidelines to Practice
      • Interpreting Key Trials
      • Letter to the Editor
      • Review
      • Smart Testing
      • Symptoms to Diagnosis
      • The Clinical Picture
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
    • Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
  • COVID-19
    • Curbside Consults Overview
    • Pulmonary/ICU
    • Patient Subsets & Specific Organ Involvement
    • Therapies
    • Imaging & Procedures
    • Patients with Underlying Disease
    • Virus Background & Testing
    • Healthcare System Practice
  • Conference Coverage
    • ASH Annual Meeting
    • AHA Sessions 2020
    • IDWeek 2020
    • CHEST 2020
    • ADA 2020
    • ACC 2020
  • Advertise
    • Media Kit
    • Contact
Editorial

Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure

George Thomas, MD
Cleveland Clinic Journal of Medicine July 2020, 87 (7) 444-447; DOI: https://doi.org/10.3949/ccjm.87a.20092
George Thomas
Director, Center for Blood Pressure Disorders, Department of Nephrology and Hypertension, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: thomasg3@ccf.org
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Procedures and devices to treat resistant hypertension in chronic kidney disease - July 01, 2020
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Thomas G,
    2. Xie D,
    3. Chen HY, et al; CRIC Study Investigators
    . Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study. Hypertension 2016; 67(2):387–396. doi:10.1161/HYPERTENSIONAHA.115.06487
    OpenUrlCrossRefPubMed
  2. ↵
    1. Gajulapalli RD,
    2. Chahine J,
    3. Rader F,
    4. Aneja A
    . Procedures and devices to treat resistant hypertension in chronic kidney disease. Cleve Clin J Med 2020; 87(7):435–443. doi:10.3949/ccjm.87a.19099
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bhatt DL,
    2. Kandzari DE,
    3. O’Neill WW, et al; SYMPLICITY HTN-3 Investigators
    . A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15):1393–1401. doi:10.1056/NEJMoa1402670
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kandzari DE,
    2. Böhm M,
    3. Mahfoud F, et al; SPYRAL HTN-ON MED Trial Investigators
    . Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391(10137):2346–2355. doi:10.1016/S0140-6736(18)30951-6
    OpenUrlCrossRefPubMed
  5. ↵
    1. Townsend RR,
    2. Mahfoud F,
    3. Kandzari DE, et al; SPYRAL HTN-OFF MED Trial Investigators
    . Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108):2160–2170. doi:10.1016/S0140-6736(17)32281-X
    OpenUrlCrossRef
  6. ↵
    1. Azizi M,
    2. Schmieder RE,
    3. Mahfoud F, et al; RADIANCE-HTN Investigators
    . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391(10137):2335–2345. doi:10.1016/S0140-6736(18)31082-1
    OpenUrlCrossRefPubMed
  7. ↵
    1. Azizi M,
    2. Sapoval M,
    3. Gosse P, et al; Renal Denervation for Hypertension (DENERHTN) investigators
    . Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multi-centre, open-label, randomised controlled trial. Lancet 2015; 385(9981):1957–1965. doi:10.1016/S0140-6736(14)61942-5
    OpenUrlCrossRefPubMed
  8. ↵
    1. Sardar P,
    2. Bhatt DL,
    3. Kirtane AJ, et al
    . Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension. J Am Coll Cardiol 2019; 73(13):1633–1642. doi:10.1016/j.jacc.2018.12.082
    OpenUrlFREE Full Text
  9. ↵
    1. Cheng X,
    2. Zhang D,
    3. Luo S,
    4. Qin S
    . Effect of catheter based renal denervation on uncontrolled hypertension: a systematic review and meta-analysis. Mayo Clin Proc 2019; 94(9):1695–1706. doi:10.1016/j.mayocp.2019.07.005
    OpenUrlCrossRef
  10. ↵
    1. Hering D,
    2. Mahfoud F,
    3. Walton AS, et al
    . Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23(7):1250–1257. doi:10.1681/ASN.2011111062
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Prasad B,
    2. Berry W,
    3. Goyal K,
    4. Dehghani P,
    5. Townsend RR
    . Central blood pressure and pulse wave velocity changes post renal de-nervation in patients with stages 3 and 4 chronic kidney disease: the Regina RDN Study. Can J Kidney Health Dis 2019 Feb 13; 6:2054358119828388. doi:10.1177/2054358119828388
    OpenUrlCrossRef
  12. ↵
    1. Mahfoud F,
    2. Böhm M,
    3. Schmieder R, et al
    . Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40(42):3474–3482. doi:10.1093/eurheartj/ehz118
    OpenUrlCrossRef
  13. ↵
    1. Spiering W,
    2. Williams B,
    3. Van der Heyden J, et al; CALM-FIM_EUR investigators
    . Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017; 390(10113):2655–2661. doi:10.1016/S0140-6736(17)32337-1
    OpenUrlCrossRef
  14. ↵
    1. Peixoto AJ
    . Is there a role for device therapies in resistant hypertension? The CON side. Kidney360 January 2020; 1(1):9–13. doi:10.34067/KID.0000742019
    OpenUrlCrossRef
  15. ↵
    1. Cooper CJ,
    2. Murphy TP,
    3. Cutlip DE, et al; CORAL Investigators
    . Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370(1):13–22. doi:10.1056/NEJMoa1310753
    OpenUrlCrossRefPubMed
  16. ↵
    1. Textor SC,
    2. Lerman LO
    . Reality and renovascular disease: when does renal artery stenosis warrant revascularization? Am J Kidney Dis 2014; 63(2):175–177. doi:10.1053/j.ajkd.2013.11.004
    OpenUrlCrossRefPubMed
  17. ↵
    1. Williams B,
    2. MacDonald TM,
    3. Morant S, et al; British Hypertension Society’s PATHWAY Studies Group
    . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386(10008):2059–2068. doi:10.1016/S0140-6736(15)00257-3
    OpenUrlCrossRefPubMed
  18. ↵
    1. Oliveras A,
    2. Armario P,
    3. Clarà A, et al
    . Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study — a randomized controlled trial. J Hypertens 2016; 34(9):1863–1871. doi:10.1097/HJH.0000000000001025
    OpenUrlCrossRef
  19. ↵
    1. Rosa J,
    2. Widimský P,
    3. Waldauf P, et al
    . Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. J Hypertens 2017; 35(5):1093–1099. doi:10.1097/HJH.0000000000001257
    OpenUrlCrossRef
  20. ↵
    1. Agarwal R,
    2. Rossignol P,
    3. Romero A, et al
    . Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394(10208):1540–1550. doi:10.1016/S0140-6736(19)32135-X
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Log in using your username and password

Forgot your user name or password?
PreviousNext
Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Cleveland Clinic Journal of Medicine: 87 (7)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 7
1 Jul 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
18 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure
George Thomas
Cleveland Clinic Journal of Medicine Jul 2020, 87 (7) 444-447; DOI: 10.3949/ccjm.87a.20092

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure
George Thomas
Cleveland Clinic Journal of Medicine Jul 2020, 87 (7) 444-447; DOI: 10.3949/ccjm.87a.20092
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • RENAL DENERVATION
    • BAROREFLEX AMPLIFICATION
    • ARTERIOVENOUS COUPLING
    • RENAL ARTERY STENTING
    • HOW SHOULD RESISTANT HYPERTENSION BE MANAGED?
    • DEVICES WOULD BE ATTRACTIVE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Procedures and devices to treat resistant hypertension in chronic kidney disease
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
  • Trials and tribulations of testosterone therapy in women: Importance of adhering to the evidence
  • Prostate cancer: To screen or not to screen? The question is complicated
Show more Editorial

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit
  • Advertise Contact

Info For

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • Advertisers
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2021 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire